Prepared remarks
Hello, everyone. Thank you for joining us, and welcome to the Nordson Corporation Third Quarter Fiscal Year 2026 Conference Call. I will now hand the conference over to Matt Matejka of Nordson. Matt, please go ahead.
Thank you. Good morning. This is Matt Matejka, Senior Director of Investor Relations. I'm here with Sundaram Nagarajan, our President and Chief Executive Officer; and Dan Hopgood, Executive Vice President and Chief Financial Officer. We welcome you to our conference call today, Thursday, August 20, to report Nordson's fiscal 2026 third quarter results. You can find both our press release as well as our webcast slide presentation that we will refer to during today's call on our website at www.nordson.com/investors. This conference call is being broadcast live on our investor website and will be available there for 30 days. During this conference call, we will make references to non-GAAP financial metrics. We've provided a reconciliation of these metrics to the most comparable GAAP metric in the press release issued yesterday. Before we begin, please refer to Slide 2 of our presentation, where we note that certain statements regarding our future performance that are made during this call may be forward-looking based upon Nordson's current expectations.
These statements may involve a number of risks, uncertainties and other factors as discussed in the company's filings with the Securities and Exchange Commission that could cause actual results to materially differ. Moving to today's agenda on Slide 3. Naga will discuss third quarter highlights. He will then turn the call over to Dan to review sales and earnings performance for the total company and the three business segments. Dan will also discuss the balance sheet and cash flow. Naga will then share a high-level commentary about our enterprise performance and provide an update on the fiscal 2026 full year guidance. We will then be happy to take your questions. With that, I'll turn to Slide 4 and turn the call over to Naga.
Good morning, everyone. Thank you for joining Nordson's Fiscal 2026 Third Quarter Conference Call. Before we begin, I would like to welcome Matt Matejka to our call in his new role of Senior Director, Investor Relations. As we announced in a previous press release, Matt has assumed Investor Relations responsibilities from Lara Mahoney, who has taken on a new role within Nordson. Matt joined Nordson in 2023 and brings over ten years of experience in financial leadership roles, most recently serving as Finance Director for our Industrial Coating Solutions division. Moving on to the financial results. I am pleased to share that the momentum driving our strong first half continued throughout the third quarter. For the first nine months of fiscal 2026, Nordson has grown revenue by 9% and adjusted earnings per share by 18% year-over-year with strong backlog giving us confidence in the rest of the year.
As our growth end markets continue to inflect, we are winning due to our unique competitive advantages and the successful execution of our Ascend Strategy. We are well positioned to continue compounding profitable growth. During the third quarter, all three segments again contributed to our organic growth performance, surpassing the high end of our sales and earnings guidance. We achieved record sales of $818 million. This is a 10% increase over the prior year, which is inclusive of 12% overall organic growth. Order entry momentum continued to accelerate, driving backlog up 35% compared to the prior year. Backlog growth was broad-based with all segments contributing, but particular strength came from our Advanced Technology and Medical segments. Solid execution and volume leverage drove record profit performance for the quarter, delivering EBITDA of $262 million, which was an all-time record and 32% of sales.
Adjusted earnings per share of $3.25 was also an all-time record for the business. This was an increase of 19% compared to prior year. I would also like to highlight our free cash flow of $237 million. Our free cash flow conversion of well over 100% of net income continues to be a strength, enabling a healthy mix of shareholder returns and reinvestment in growth. Our balance sheet continues to be in a strong position, giving us plenty of flexibility for future acquisitions that meet our strategic and financial criteria. I'll talk more about enterprise performance in a few moments. But first, I'll turn the call over to Dan to provide detailed perspective on our financial results for the quarter.
Thank you, Naga, and good morning, everyone. On Slide 5, you'll see we achieved record level sales of $818 million in the third quarter, up 10% from prior year third quarter sales of $742 million. The third quarter fiscal 2026 sales included an organic increase of 12%, driven by growth in all three of our segments. Currency translation was effectively neutral for the period. Strong organic sales performance was slightly offset by the net impact of the medical contract manufacturing divestiture completed in the fourth quarter of last year and the small contribution from the Capstan acquisition that was completed during the second quarter of this year. Adjusted operating profit increased 13% year-over-year to a record $226 million or 28% of sales, driven by increased leverage on the strong organic sales growth across the segments. EBITDA was up 10% year-over-year to $262 million, also a new company record.
EBITDA margin as a percent of sales was 32%, in line with the prior year. Incremental EBITDA contribution in the quarter was just shy of 32%. We are quite pleased with these operating results, which reflect our focus on maximizing growth potential while protecting our best-in-class margins and effectively managing near-term inflationary pressures tied to the broader market and geopolitical factors. In addition, we continue to reinvest and innovate to maintain our strong value proposition for many years to come. Looking at nonoperating income and expenses, net interest expense during the quarter was $20 million, a decrease of over $5 million versus the prior year, which is really driven by two key factors. One, our strong cash generation through the first nine months has allowed us to significantly delever our balance sheet. In addition, our average borrowing cost has improved year-over-year due to lower market rates on our variable debt, including the benefits from the recently announced commercial paper program that was launched during the quarter.
Other expenses on a GAAP basis increased $14 million year-over-year with the primary driver being a $15 million noncash mark-to-market charge for minority investments. These noncash valuation adjustments are subject to market volatility, and on a year-to-date basis, the impact is actually negligible. Excluding this noncash charge, other expenses net decreased by a nominal $1 million year-over-year. Our tax expense on a U.S. GAAP basis was $33 million for an effective tax rate of 17.8%, inclusive of the impact of the noncash loss I just mentioned and acquisition-related amortization and costs. On an adjusted basis, our effective tax rate was 18.3%, in line with the prior quarter run rate. For the full year, we expect our tax rate to be near 18%, which is also reflective of our ongoing rate expectations. GAAP net income in the quarter totaled $153 million or $2.73 per share. Excluding acquisition-related amortization costs and the noncash loss, adjusted earnings per share totaled a record $3.25 per share, $0.10 above the high end of our guidance range and a 19% increase from prior year adjusted earnings per share of $2.73.
To wrap up our consolidated summary, the improvement in year-over-year earnings and record Q3 results reflect strong sales growth across our portfolio, which I'll cover a bit more in a moment. It also reflects strong delivery execution driven through our Ascend Strategy and NBS Next framework. Our differentiated products, market position and commercial and operational execution have allowed us to grow our adjusted earnings per share 18% year-over-year through the first nine months of the year with strong momentum heading into the fourth quarter. Now let's turn to Slides 6 through 8 to review the third quarter fiscal 2026 segment performance. Industrial Precision Solutions sales were $367 million, an increase of 5% compared to the prior year third quarter. Organic sales increased 3% compared to the prior year with a favorable currency impact of 1% and an acquisition contribution of roughly 1%.
Organic growth was driven by packaging and industrial coatings application demand and continued recovery in our plastics processing demand. Broadly speaking, aftermarket demand remains stable across our IPS portfolio, while systems demand for broader industrial and agricultural markets remain stable but with limited growth. EBITDA was $130 million in the quarter or 35% of sales, which is in line with the third quarter of last year as we continue to invest in innovation while mitigating selected near-term inflationary pressures. Turning to the Medical and Fluid Solutions segment, sales were $231 million, a quarterly record. Total sales increased 5% compared to the third quarter of last year, while organic sales increased closer to 11% in the quarter, driven by contributions from both our engineered fluid solutions and medical product lines. Divested sales from the medical contract manufacturing business had a negative impact of approximately 6% compared to the prior year.
Medical component demand has normalized, and we're now seeing stable ongoing growth in many of our product lines, while we're also seeing broad-based demand for fluid solution systems applications in medical and electronics markets. EBITDA for Medical and Fluid Solutions was a record $88 million or 38% of sales, which is an increase of 6% from prior year EBITDA of $83 million. The segment delivered strong year-over-year incrementals during the quarter and EBITDA margins improved about 100 basis points sequentially on the higher sales. Turning to Advanced Technology Solutions, you'll see sales were an all-time quarterly record of $220 million, a 28% increase compared to the prior year's third quarter. Organically, sales increased 31% with growth coming across both the Electronics Dispense and Test and Inspection product lines, reflecting the continued strength in semiconductor and broadening electronics end market demand.
Third quarter EBITDA was also an all-time quarterly record of $66 million, driving a record EBITDA margin of 30% of sales. EBITDA increased 58% compared to the prior year third quarter EBITDA of $42 million or 24% of sales. The improvement in EBITDA margin reflects the record sales volumes and strong operational leverage driven by improvements we've made in our operations over the last several years. Finally, turning to the balance sheet and cash flow, at the end of the third quarter, we had cash on hand of $113 million and net debt was approximately $1.6 billion. We've continued to delever with our leverage ratio decreasing further to 1.7x, which is made possible by our strong earnings and cash flow generation. This provides us with significant firepower to strategically deploy capital, including returning cash to shareholders, reinvesting for growth and acquiring strategic assets. Our free cash flow generation during the quarter was $237 million, resulting in a 144% conversion rate on net income, excluding the noncash loss that I mentioned a moment ago.
This is up from 113% through the first half of this year, and the third quarter represents the fifth consecutive quarter of delivering well over 100% conversion. As noted on Slide 10, our capital allocation continues to be balanced and is driving value, fueled by our strong cash flow generation. Year-to-date, in addition to our acquisition of CapstanAG announced last quarter, we've invested $40 million in capital projects to support current and future organic growth opportunities. Through nine months, we've also returned capital to shareholders with $137 million in dividends paid and $159 million of shares repurchased. We've been able to do all of this while reducing our net debt and reducing our leverage ratio, positioning us well to pursue strategic growth opportunities. So to summarize and close, we delivered another quarter of fantastic record results. Each of our segments delivered record third quarter sales and strong organic growth.
And in the case of Medical and Fluid Solutions and Advanced Technology Solutions, all-time record quarterly sales. EBITDA margins remain strong and cash conversion is a continuing strength, reflecting solid earnings quality and disciplined working capital management. This provides us all the flexibility needed to strategically deploy capital to sustainably grow and return value to shareholders. Our teams once again delivered on their commitments for the quarter and continued to grow our backlog, which puts us in a great position heading into the fourth quarter. As Naga will address next, our portfolio position and NBS Next framework support continued growth into the future, positioning us well to continue delivering for our stakeholders. With that, let's turn to Slide 11, and I'll turn the call back to Naga.
Thanks, Dan. It's been a very strong fiscal nine months for Nordson. As our end markets continue to inflect, the execution of our Ascend Strategy positions us well to deliver for our customers. As we look at Slide 11, I want to take a moment to remind our investors about Nordson's competitive advantages, which have positioned us to reliably compound profitable growth. From the very beginning, Nordson built a business model based on three key strategic themes: differentiated products, close-to-customer relationships and diversified niche end markets. Our founder started this company through the purchase of patented technology, understanding the importance of differentiation. Our legacy was then built through close customer relationships where we solve problems together and advanced technology road maps. Over the past 70 years, Nordson's innovation has led to market leadership in precision technologies, speed and efficiency in diverse niche end markets.
We have built upon these core strengths with the addition of the NBS Next growth framework, which is how we run the company. Our decentralized divisions use this framework to focus on the best market growth opportunities, top products and customers to deliver above-market organic growth. We have also been very intentional in building a growth-biased portfolio of precision technologies with reduced cyclicality over time. Some of you may recognize Slide 12 from our 2024 Investor Day. Approximately 60% of this portfolio generates recurring revenue, including aftermarket parts, consumables and services. Importantly, more than 50% of our portfolio is now in growth end markets, including semiconductor, electronics and medical with the remaining exposures in more stable GDP-plus end markets. Our portfolio positioning gives me confidence in our growth aspirations for the remainder of the year and beyond.
Turning now to our outlook on Slide 13. We entered the fourth quarter with backlog up 35% year-over-year. Based on the momentum in our end markets, as evidenced by our backlog and order entry, we are increasing our full year guidance. Sales are now expected to be in the range of $3.035 billion to $3.075 billion and adjusted earnings to be in the range of $11.80 to $12.00 per diluted share, putting us on the high end of our previously communicated average growth algorithm. Our updated guidance reflects sustained order strength and our ability to deliver results through NBS Next. We also assume FX rates hold at current levels, which implies a neutral impact on the fourth quarter. As always, I want to thank our customers and shareholders for your continued support. In particular, I want to thank Nordson employees who are passionate about meeting the needs of our customers. Our focus on innovation and operational excellence continue to position us well to serve our customers. With that, we will pause and take your questions.
Questions and answers
Your first question is from Mike Halloran from Baird.
So a couple of questions here. Could you just put the backlog in context for us? Obviously, quite strong backlog growth. Have you seen any elongation in lead times? What kind of visibility does it give you into next year? And anything from a historical perspective that you think is worth bearing in mind here as we think about the magnitude of that gain?
Sure. Mike, this is Dan. I appreciate the question. A couple of things. Number one, I'll highlight again, as we mentioned, the backlog growth that we're seeing is broad-based. All three of our segments are showing higher backlog year-over-year. But I would say, in general, no real departure from what I would call normal order patterns. Again, just to recap some things that we've said in the past and are still true today. Our backlog, generally speaking, turns over in about six months. The majority of our backlog ships within about six months. So clearly, as of the end of the third quarter, we're taking orders into 2027 at this point, but no elongation in lead times. Our lead times have actually been reduced over the years. So if anything, I would say we're able to deliver faster than we have in the past. But no real change in order patterns. I would say normal recurring order patterns. At this point, our backlog is normal turnover of roughly six months, 80% or so of our backlog is going to turn over with a few long lead time items with some of our larger systems, which is very typical.
Yes. Maybe add a little bit of color there, Mike, around lead time. In general, with our Ascend Strategy and NBS Next over this period of time, if you think about our lead times, they have generally reduced. And routinely, we have the opportunity to gain share because we are able to have shorter lead time than the rest of the team in the marketplace. Our on-time delivery has significantly improved across the company in just about every division. We have gone over this period of time; routinely, we will ship 80% to 95% in most of our businesses. So a good strength for us to be able to deliver when the customer wants it. I think that is probably critical because some of these lead times are also dictated by the customers' needs in relationship with the other things that they're putting together in a line.
And then second question, just maybe give some more context on what you're seeing in the ATS segment, specifically within the Test & Inspection and dispensing. Maybe just break out the two dynamics you're seeing there? And any nuance you think is relevant versus what you're seeing in the market today?
Yes. Broad-based growth in the quarter with both our dispense business and Test & Inspection business. Clearly, the dispense business is typically ahead of the curve in terms of growth cycle, and that's what we saw. In the quarter, certainly, our Test & Inspection businesses continue to grow nicely, a good inflection point both for our X-ray and optical businesses. If you remember, these technologies are critical in ensuring semiconductor packaging. We are also seeing growth reflected in our EFD business, which is part of our Medical and Fluid Solutions segment. So feel good about order entry, pipeline activity and customer conversations for both dispense and Test & Inspection. A lot of this demand allows us to not only be quite confident about what we're going to deliver in Q4, but well into next year.
Your next question is from Jeff Hammond with KeyBanc Capital Markets Inc.
So maybe just to stay on whether it's backlog or orders or the guide. It seems like the stark beat in the quarter is ATS. So I'm just trying to, maybe you can unpack the $0.35 raise between the businesses. It doesn't seem like the other two segments are moving that much, which goes back to your comment that you're seeing broad-based growth. I'm just trying to understand how differentiated the ATS is versus the other two segments?
Yes. I guess maybe just to give a little color on it. I would say, broadly speaking, IPS is as expected as we think about heading into the quarter and then how we finished in our outlook. I would say the upside that we're seeing certainly in the third quarter, but even in our outlook for Q4, is that ATS is a big driver, but I would say Medical is the other area that we're seeing acceleration. And maybe just to go back to our pre-Q3 commentary, we said, look, if order momentum sustained, I think we said we felt comfortable we'd probably be on the higher end of our guidance. I would say in both Medical and ATS, order momentum not only sustained, but actually accelerated in some areas. And so I would say it's those two segments driving the increased outlook for the year. But again, I think on the IPS side, no surprise, I think just kind of steady state with IPS.
Right. Jeff, if you would sort of compare against long-term targets for these growth rates of these businesses to put it in context, clearly, ATS was significantly higher than our long-term target. And we are at the peak of the cycle, and we're starting to really have legs to this cycle even more than we were. So we're on the upside of the cycle, and hence, you see some very elevated growth rates. But IPS, for example, it's 50% of the company. We're at our long-term goal of growing 3% in the quarter. And for the first nine months, again, growing over 3%. That number is not big when compared to the 30-plus percent in ATS, but 3% for this business is pretty strong. And if you think about Medical and Fluid Solutions, that's even a better story where our long-term expectations are 6% to 7% growth rates. And in the quarter, they were 11%. And clearly, there is some benefit from the EFD business that has some electronic exposure. But even if you take that out, I would say medical businesses are trending towards where our long-term targets are, and we really feel good about where we're headed into next quarter and the following year.
Okay. Great. And then just on IPS, I think for all year, the margins, obviously very good, but down year-on-year. And I think you mentioned price/cost dynamics. Just talk about the margin dynamic. And I think you mentioned prioritizing growth and balancing that with margins. So just speak to IPS margins. And then just while we're on it, did you have any tariff refunds? Are those to come? Will you exclude those kind of thing?
Yes. Both great questions. So let me start with margins. I'll reiterate margin expectations. There is really no fundamental change in margin expectations. Our target incrementals are 35% to 40%. That's consistent across all three of our segments. But I will say that these are long-term targets, and in any given year, we may do better or worse given different dynamics that are going on in the market. Given the current market dynamics, our focus is really maximizing growth potential and maintaining margin performance, which is already very strong, certainly within the IPS business. If you look at our margins of 35% in the quarter, it's in line with where we've been. We're holding serve while maximizing our growth potential. I think that's the right playbook for IPS in the current market dynamics. No fundamental change in the margin profile, no fundamental change in our long-term targets, but there's plenty of room for margin enhancement in the future.
We think the right playbook is to focus on growth and maintain our margin position today. Your second question on tariffs: a couple of things. Tariffs in themselves have not had a material impact on Nordson. That said, where we have potential, we are pursuing recoveries for selected tariffs like everybody else. But in the context of tariffs not having a material impact overall and the fact that those recoveries are only a portion and offsetting any ongoing tariff impact in the context of our overall results, tariffs and tariff recoveries are really not a significant item to talk about. That said, we are seeing, through the direct and indirect impact of tariffs as well as other geopolitical events, general inflationary pressures that we are managing and mitigating our way through while maximizing our growth potential. That has broader implications if you think about freight and selected commodities. So more of a general pressure that is tied to but not directly related to tariffs.
But put all of it together, the company is still delivering 32% EBITDA, with each of the segments delivering best-in-class margins. We are managing through all of these different pressure points, while continuing to stay focused on what is the best value creation opportunity for Nordson, which is really profitable growth. That's what you're seeing play out in the first nine months of the year as well as in the quarter.
Your next question is from Matt Summerville with D.A. Davidson.
Just on the Medical and Fluid Solutions segment, can you maybe just give a little bit more granularity on what you're seeing between the EFD business versus medical components versus interventional, kind of just parse that out a bit around that 11% organic? And then specifically for that business, what's kind of implied in organic for the fourth quarter?
So we don't typically give segment-level detail on our outlook, but let me address the first part of your question. The 11% growth that we're seeing in the quarter is pretty broad-based. Relative to EFD, one of the drivers is electronics-based demand, and we're seeing nice growth and ongoing demand in our order outlook for that space. But we are seeing pretty broad-based growth and order demand in the medical component space as well. That would include the interventional space, some of our medical specialty products and our fluid components products. Even within EFD, a significant portion of EFD's business is actually tied to medical investments. So pretty broad-based. I wouldn't say it's across-the-board growth yet in medical, but in all spaces, based on actual performance in Q3, what's on our order board and our pipeline, we're walking our way right back to our ongoing normal mid-single-digit-plus growth in our medical components business. Some are already there, some are on their way there.
And then, Naga, if you could just speak to the ATS business, how you're thinking about cycle durability, how long this cycle extends? Any early views you have on fiscal 2027 growth in that business, given you're going to have tougher comps versus this year, but really want to understand how this cycle feels versus prior cycles.
Clearly, based on what we see in our businesses, our pipeline activity with customers, order entry, backlog buildup and revenue delivery, if you think all four of those things together and think about our dispense business, our Test & Inspection business and our exposure in EFD to electronics, all of them indicate that we still have room in this cycle. We are headed to delivering what looks like a very strong, likely all-time record. In the quarter, we delivered an all-time record for this segment. We feel really good about where we are and where we are going. To address your question directly, this quarter we delivered 30% organic growth in this segment, which is fantastic. As we head into next year, our expectation is we'll build off of this peak and then grow at a rate more in line with our longer-term mid-single-digit target. Think of this as building off an all-time peak. Everything we see in the business and what we follow for our customers indicates demand looks strong going into fiscal 2027. One point of clarification: investments in chip manufacturing infrastructure in North America have not yet translated into orders for Nordson. That is to come. Much of the current demand we're fulfilling today is in Asia. As North American chip infrastructure gets built out, that's another opportunity for Nordson, and we are yet to see that materialize.
Your next question is from Christopher Glynn with Oppenheimer & Co.
I wanted to ask about the IPS segment. Over the years, you have some step-out opportunities, cans, coatings, recycling come to mind. Wondering if there are any emerging applications or market adoption opportunities for polymers, coatings or core adhesives that are popping up in the pipeline?
If you think about our IPS business, it thrives on finding applications or pivoting to end market niches where the growth is. We continue to build out new applications. I wouldn't say anything is popping up as a headline today, but we are certainly watching growth. For example, battery and solar are early-stage opportunities in terms of how IPS applications will play in defense and certain data center build-out applications. These are early stages. We have multiple single applications in many different end markets. For example, our powder coating business is doing incredibly well this year because it addresses multiple end market applications. But I wouldn't point to a single breakout application to highlight right now.
And then the fourth quarter implies a pretty meaningful acceleration in sequential incrementals. I know you had that and then some last year fourth quarter over third quarter. We're in a year of managing inflation, as you've described in detail. So just curious, relative stability sequentially in the third quarter, and it looks like the fourth quarter has a meaningful ramp without a pronounced sequential volume lift. Can you comment?
I appreciate the observation. That ramp is tied to normal operational improvements and enhancements that we continually work on. We have good line of sight to that. We tend to look at margins more as an average over time rather than on any given quarter. There's a nice step-up in profitability tied to mix and our outlook, but also tied to ongoing operational initiatives and their impact. On a year-over-year basis, incrementals are a little more challenging because the fourth quarter of last year was a bit of an outlier from a profitability standpoint. But overall, we're on track with our average annual growth algorithm and margin expectations, and Q4 is reflective of that.
The simpler way to think about Nordson going forward is we want to maximize our best growth opportunities and deliver against our growth commitments with best-in-class margins. We continue to focus on organic growth improvement and maximize all the end market opportunities where we have a right to play.
Okay. And last one, to the lower end on the tax rate, this has been a trend a couple of years. So clearly doing an excellent job with the tax model, and you indicated stability into next year. How would you describe the longer-term tax rate opportunity from here in the context of the progress in the last few years?
As I said earlier, 18% is reflective of our ongoing rate expectation. We think that's a good spot to be in, and it's reflective of our ongoing run rate. It's something we continue to look at and assess, but 18% is a good long-term expectation going forward.
Your next question is from Andrew Buscaglia from BNP Paribas.
This is Ed on for Andrew. Many of my questions were already asked, but I wanted to touch on M&A. You pointed out the 1.7x leverage. With sales firing on most cylinders, you're going to be driving some strong free cash as well. Just wondering if you could provide some color on the M&A pipeline, what you're seeing and whether there may be some end markets which are more or less attractive from a valuation perspective or otherwise.
M&A is an important part of Nordson's growth algorithm. We continue to spend time on it and have a healthy number of opportunities. We pursue opportunities that meet our strategic and financial criteria. We've demonstrated we will do various sizes and types of deals. Most recently, we did a small bolt-on acquisition with CapstanAG; the prior year we had Atrion. We continue to stay focused on acquisitions, but not announcing anything significant doesn't mean we're not working on it. Oftentimes, things are not appropriate from a strategic or financial return perspective. Our strategic criteria are attractive end market niches and applications, differentiated technologies and clearly adding to our growth-focused portfolio. Financially, we want growth above market with Nordson-like margins and returns that sufficiently exceed our cost of capital. We're spending a lot of time around our medical platform, continuing to expand it. As with Capstan, we'll continue to add bolt-on assets to strong existing core franchises. We will do both bolt-ons and larger deals and continue to look at test and inspection as well as other areas.
The only thing I'd add is our growth algorithm: on average over time, half our growth comes from organic and half from inorganic. We still think that's the right long-term formula. We're actively working the M&A piece, but broadly that's still the right way to think about it over time.
Yes. But we have to stay disciplined, and that's what you're seeing from the company: staying disciplined with the right kind of assets that fit both strategic and financial criteria.
There are no further questions at this time. I will now turn the call back to Naga for closing remarks.
Thank you for your time and attention on today's call. Nordson is well positioned as a diversified precision technology company. Our close-to-customer model, proprietary and niche technology, diversified geographic and end market exposures, high level of recurring revenue and strong balance sheet are among the many attributes that make us a quality growth compounder. Have a great day.
This concludes today's call. Thank you so much for attending. You may now disconnect.